<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768842</url>
  </required_header>
  <id_info>
    <org_study_id>16494</org_study_id>
    <secondary_id>I8H-MC-BDCJ</secondary_id>
    <secondary_id>2020-003738-19</secondary_id>
    <nct_id>NCT04768842</nct_id>
  </id_info>
  <brief_title>A Study of Two Different Formulations of LY3209590 in Healthy Participants</brief_title>
  <official_title>Comparative Pharmacokinetics of LY3209590 After Administration of a Lyophilized Formulation and a Solution Formulation in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to look at the amount of the study drug, LY3209590, that&#xD;
      gets into the blood stream and how long it takes the body to get rid of LY3209590 when given&#xD;
      as different formulations. The tolerability of LY3209590 will also be evaluated and&#xD;
      information about any side effects experienced will be collected. The study will last up to&#xD;
      142 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Actual">September 3, 2021</completion_date>
  <primary_completion_date type="Actual">September 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3209590</measure>
    <time_frame>Predose on Day 1 through Day 65</time_frame>
    <description>PK: Cmax of LY3209590</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3209590</measure>
    <time_frame>Predose on Day 1 through Day 65</time_frame>
    <description>PK: AUC(0-inf) of LY3209590</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3209590 Lyophilized Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 as lyophilized formulation administered subcutaneously (SC) in one of the two study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3209590 Solution Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3209590 as solution formulation administered SC in one of the two study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3209590</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3209590 Lyophilized Formulation</arm_group_label>
    <arm_group_label>LY3209590 Solution Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or non-pregnant females. Additionally, women of childbearing&#xD;
             potential must test negative for pregnancy&#xD;
&#xD;
          -  Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/mÂ²), inclusive&#xD;
             at screening&#xD;
&#xD;
          -  Have blood pressure, pulse rate, blood and urine laboratory test results that are&#xD;
             acceptable for the study&#xD;
&#xD;
          -  Have veins suitable for blood sampling&#xD;
&#xD;
          -  Have given written informed consent approved by Lilly and the ethical review board&#xD;
             governing the site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have or used to have health problems that, in the opinion of the doctor, could make it&#xD;
             unsafe to participate, or could interfere with understanding the results of the study&#xD;
&#xD;
          -  Are women who are pregnant or lactating&#xD;
&#xD;
          -  Have a history of multiple and/or severe allergic reactions&#xD;
&#xD;
          -  Show clinical evidence of HIV, hepatitis C, or hepatitis B, and/or test positive&#xD;
&#xD;
          -  Regularly use known drugs of abuse or with positive drug results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 15, 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

